


In Bavaria¹, biosimilar competition led to rheumatic patients receive **faster access to biological therapy²**

Waiting time for biological therapy in years



Market launch of Biosimilars against rheumatism:

2015
Infliximab

2016:
Etanercept

2018:
Adalimumab

Biosimilar infliximab, etanercept and adalimumab use translated in a significant reduction of the duration of synthetic medicines therapy for rheumatic patients from 7,4 years to 4 months²

*until 2015, exclusively synthetic standardised therapy or original biological agents were available³

Source: 1. Bavaria, Germany, 2. ProBiosimilars preliminary results of the PHARAO study - <https://probiosimilars.de/presse/versorgung/studie-biologika-und-rheuma-patienten/> 3. AG Pro Biosimilars, patient survey at the DocCheck rheumatologist